argen-x initiates a second pre-clinical development program in under 18 months from start of operations
argx-110 to target autoimmune, inflammation and oncology indications
17-May-2011 -
arGEN-X announced that it has progressed ARGX-110, its second therapeutic candidate, into formal pre-clinical development in less than 18 months since the Company began its operations.ARGX-110 is a completely novel, fully human antibody specific for an undisclosed, clinically validated cell ...
autoimmune diseases
human antibodies
inflammation
+1